Segall Bryant & Hamill LLC Takes $5.45 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Segall Bryant & Hamill LLC acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 59,106 shares of the medical instruments supplier's stock, valued at approximately $5,446,000. Segall Bryant & Hamill LLC owned approximately 0.26% of LeMaitre Vascular as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Copeland Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 0.7% in the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock worth $107,990,000 after purchasing an additional 8,623 shares during the period. State Street Corp increased its stake in LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock worth $76,363,000 after acquiring an additional 28,525 shares during the last quarter. Congress Asset Management Co. raised its holdings in shares of LeMaitre Vascular by 1.8% in the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock valued at $66,555,000 after acquiring an additional 13,009 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of LeMaitre Vascular by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier's stock valued at $50,403,000 after acquiring an additional 23,443 shares during the last quarter. Finally, DF Dent & Co. Inc. grew its holdings in shares of LeMaitre Vascular by 26.2% during the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier's stock worth $24,037,000 after purchasing an additional 53,797 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LMAT shares. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital raised their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $95.25.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This represents a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Stock Performance

LMAT traded up $1.26 on Tuesday, hitting $85.16. 195,293 shares of the company were exchanged, compared to its average volume of 154,456. The firm has a fifty day simple moving average of $92.47 and a two-hundred day simple moving average of $94.36. The stock has a market capitalization of $1.92 billion, a PE ratio of 46.54, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.94%. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular's dividend payout ratio is 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.